|
Median age
| |
73.08 (range 54–87)
|
71.63
|
74.13
| |
|
Sex
|
female
|
16
|
6
|
10
|
0.41
|
|
male
|
10
|
5
|
5
|
0.41
|
|
Hospitalization on septic/non-septic ward
|
septic ward
|
21
|
7d
|
14
|
0.04
|
|
all other wards
|
5
|
4 b,c
|
1
| |
|
Primary diagnosis
|
periprosthetic infection
|
19
|
8
|
11
|
0.81
|
|
soft tissue / wound infection
|
4
|
1
|
3
| |
|
spondylitis
|
2
|
2
|
0
| |
|
osteomyelitis
|
1
|
0
|
1
| |
|
Co-morbidities
|
renal insufficiency
|
12
|
4
|
8
|
0.41
|
|
diabetes
|
11
|
5
|
6
| |
|
pneumonia
|
1
|
0
|
1
| |
|
neoplasm
|
2
|
1
|
1
| |
|
hepatic disease
|
2
|
1
|
1
| |
|
Antimicrobial therapy
|
aminopenicillins
|
4
|
1
|
3
|
0.72
|
|
ureidopenicillins
|
6
|
2
|
4
|
0.42
|
|
fluoroquinolones
|
9
|
3
|
6
|
0.27
|
|
cephalosporins
|
13
|
5
|
8
|
0.24
|
|
clindamycin
|
7
|
3
|
4
|
0.81
|
|
rifampicin
|
13
|
6
|
7
|
0.69
|
|
Gastric acid suppressors
|
proton pump inhibitors/H2 blockers
|
25
|
11
|
14
| |
|
Severity factors
|
creatinine (>1.5x103g/L)
|
7
|
3
|
4
|
0.99
|
|
leukocytosis (>1.5x109/L)
|
10
|
4
|
6
|
0.93
|
|
Antimicrobial CDI treatment
|
|
First episode
|
metronidazole po.
|
18
|
8
|
10
| |
|
vancomycin po.
|
1
|
0
|
1
| |
|
metronidazole iv. vancomycin po.
|
2
|
unknown
|
unknown
| |
|
fidaxomicin po.
|
4
|
1
|
3
| |
|
colectomy
|
1
|
0
|
1
| |
|
no treatment
|
1
|
0
|
1
| |
|
Recurrence
|
vancomycin po.
|
5
|
2
|
3
| |
|
metronidazole iv. + vancomycin po.
|
1
|
0
|
1
| |
|
fidaxomicin po.
|
3
|
1
|
2
| |
|
fecal biota transplantation
|
1
|
0
|
1
| |
|
Clinical outcome
|
cure
|
15
|
9
|
6
|
0.21
|
|
recurrence
|
10
|
3
|
7
|
0.37
|
|
death within 6 months
|
4
|
0
|
4
|
0.13
|
|
death CDI attributed
|
1
|
0
|
1
| |
|
death CDI contributed
|
3
|
0
|
3
| |
